Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Activists also report to the SEC on NewAmsterdam Pharma, Tennant, Colliers International Group, and Kinetik Holdings. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
NewAmsterdam Pharma N.V. - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood…
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 1…
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma N.V. - First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib…
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company's book value. With the stock now some dis…
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris Therapeutics (ACRS) shares ended the last trading session 6% higher at $5.64. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8% loss ove…
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading
Novartis Trial Failure Sparks Biopharma Options Frenzy
Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector. NVS is headed for its worst single-session performance on re…
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading
Why the Dow is being dragged down by a Swiss company’s bad news
Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday. - Fabrice Coffrini/Agence France-Presse/Getty Images Investors returning from the Labor Day break could be forgiven for wondering if their eyes were dece…
Novo Nordisk faces fresh setback as it halts two heart drug trials
[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer Novo Nordisk (NVO [https://seeki…
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
[Scientist use ai technology, biotechnology for Medical research and development of scientific lab. Medical Research Laboratory for Test and analysis chromosome DNA genetic.] Swiss drugmaker Novartis' (NVS [https://seekingalpha.com/symbol/…
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-rec…
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
NewAmsterdam Pharma N.V. – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from…
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam, Menarini Secure Positive CHMP Opinion For Obicetrapib & Evlarco To Treat Cholesterol
(RTTNews) - NewAmsterdam Pharma Company N.V. (NAMS), a late-stage clinical biopharmaceutical company and partner Menarini Group, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has…
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma N.V. - Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, an…
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Attovia Therapeutics, Inc. Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Com…
Attovia Therapeutics Appoints John W. Smither to Board of Directors
SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unm…
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, ha…
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, ha…
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, ha…
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NewAmsterdam Pharma N.V. NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing…
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicine…
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Recent trading context for NewAmsterdam Pharma (NasdaqGM:NAMS) NewAmsterdam Pharma (NasdaqGM:NAMS)…
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026
We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Druc…
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing…
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securitie…
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
Key Points FCPM III Services B.V. initiated a new position in Damora Therapeutics, adding 2,441,000 shares last quarter; the estimated trade size was $65.63 million (quarterly average pricing). The quarter-end value of the new Damora Thera…
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi…